Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cronos Group Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Cronos Group Inc trades at $2.76 (market cap $1.02B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 39.1× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CRON | |
|---|---|---|
Market Cap | $39.89B | $1.02B |
Sector | Health | Health |
52-Week High | $491.22 | $3.27 |
52-Week Low | $278.09 | $1.95 |
Enterprise Value | $38.15B | $200.66M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CRON trades at $2.75, down 1.08% today. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent Q1 2026 earnings met expectations with $0.01 EPS, and the company expanded its Spinach brand and international footprint.
Outlook is mixed; strong revenue growth and market share gains in Canada and Israel offer upside, but profitability challenges and intense cannabis competition pose risks. Analyst consensus is cautious with 60% hold ratings. Key catalysts include continued international expansion and execution on cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
